Longboard Pharmaceuticals, Inc. stock is down -27.63% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November.
Longboard Pharmaceuticals, Inc. focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.